MedTrace Logo

Dyslipidemia in Type 2 Diabetes (0767-034)

NCT00547274 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 111

Last updated 2015-06-12

No results posted yet for this study

Summary

The purpose of the study is to compare the lipid-altering effects of MK0767, glipizide, and pioglitazone after 12 weeks of treatment.

This is an early phase trial and some specific protocol information is in progress and not publicly available at this time. (Full information is available to trial participants).

Conditions

Interventions

DRUG

MK0767

Sponsors & Collaborators

Principal Investigators

  • Medical Monitor · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-07-31
Primary Completion
2003-11-30
Completion
2003-11-30

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00547274 on ClinicalTrials.gov